{"id":"daily-tdf-ftc","safety":{"commonSideEffects":[{"rate":null,"effect":"Renal dysfunction / decreased glomerular filtration rate"},{"rate":null,"effect":"Bone mineral density loss"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside/nucleotide reverse transcriptase inhibitors that work synergistically to inhibit HIV reverse transcriptase, preventing the conversion of viral RNA to DNA and blocking HIV replication. This combination is used both as antiretroviral therapy for HIV-infected individuals and as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in high-risk populations.","oneSentence":"TDF/FTC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:35.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 prevention (pre-exposure prophylaxis, PrEP)"},{"name":"HIV-1 treatment as part of antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570},{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT02881320","phase":"PHASE2, PHASE3","title":"Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-09-21","conditions":"HIV-1 Infection","enrollment":177},{"nctId":"NCT07071623","phase":"PHASE3","title":"A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-10","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4580},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT07044297","phase":"PHASE3","title":"A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-31","conditions":"Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis","enrollment":4390},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT07476339","phase":"PHASE4","title":"REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks","status":"NOT_YET_RECRUITING","sponsor":"CAN Community Health","startDate":"2026-03-23","conditions":"HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV","enrollment":200},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT06511063","phase":"PHASE2","title":"Antiviral Clinical Trial for Long Covid-19","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-10-01","conditions":"Long Covid","enrollment":90},{"nctId":"NCT07202546","phase":"PHASE2","title":"A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-02-11","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT07462611","phase":"NA","title":"HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-03-30","conditions":"HIV Pre-exposure Prophylaxis, PrEP","enrollment":250},{"nctId":"NCT07001319","phase":"PHASE1","title":"Study of GS-3242 in Participants With HIV-1; Substudy-05","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-05-29","conditions":"HIV-1-infection","enrollment":30},{"nctId":"NCT06101342","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":181},{"nctId":"NCT07288190","phase":"PHASE2","title":"Phase 2b, Open Label, Multisite, Randomized Crossover Study of DPP Versus 2PR","status":"NOT_YET_RECRUITING","sponsor":"HIV Prevention Trials Network","startDate":"2026-05-15","conditions":"Pregnancy, HIV Infections","enrollment":300},{"nctId":"NCT06435026","phase":"PHASE2","title":"Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-06-18","conditions":"HIV, Prevention, Pregnancy","enrollment":54},{"nctId":"NCT04898699","phase":"EARLY_PHASE1","title":"IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya","status":"COMPLETED","sponsor":"Columbia University","startDate":"2021-11-24","conditions":"HIV","enrollment":120},{"nctId":"NCT06104306","phase":"PHASE4","title":"Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-12-13","conditions":"HIV-1-infection","enrollment":33},{"nctId":"NCT07390409","phase":"","title":"ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.","status":"NOT_YET_RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2026-01-29","conditions":"HIV","enrollment":3700},{"nctId":"NCT05052996","phase":"PHASE2","title":"Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-10-05","conditions":"HIV-1 Infection","enrollment":142},{"nctId":"NCT04644029","phase":"PHASE3","title":"Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-24","conditions":"HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis","enrollment":730},{"nctId":"NCT04820933","phase":"EARLY_PHASE1","title":"Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-03-01","conditions":"HIV I Infection, Cardiovascular Risk Factor, Lipid Metabolism Disorders","enrollment":26},{"nctId":"NCT04233879","phase":"PHASE3","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"HIV-1 Infection","enrollment":599},{"nctId":"NCT04564547","phase":"PHASE2","title":"Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-09","conditions":"HIV-1 Infection","enrollment":161},{"nctId":"NCT07336797","phase":"PHASE2","title":"Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy","status":"RECRUITING","sponsor":"Abdelrahman Mahmoud","startDate":"2025-09-01","conditions":"Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)","enrollment":66},{"nctId":"NCT01854775","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05-06","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":129},{"nctId":"NCT06203132","phase":"PHASE3","title":"DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-01-27","conditions":"HIV-1-infection","enrollment":610},{"nctId":"NCT06544733","phase":"PHASE2, PHASE3","title":"Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-20","conditions":"HIV-1-Infection","enrollment":675},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT04925752","phase":"PHASE3","title":"Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-06-28","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":3292},{"nctId":"NCT04782180","phase":"PHASE4","title":"PrEP at a Syringe Services Program","status":"COMPLETED","sponsor":"University of Miami","startDate":"2022-02-01","conditions":"Hiv, Substance Use Disorders","enrollment":90},{"nctId":"NCT03696160","phase":"PHASE3","title":"The Late Presenter Treatment Optimisation Study","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2019-03-05","conditions":"HIV/AIDS","enrollment":447},{"nctId":"NCT04222504","phase":"NA","title":"Community-based Venues for Delivery of Healthcare Services: Proof of Concept Pilot","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-02-08","conditions":"Pre-Exposure Prophylaxis, STI, Contraceptive Usage","enrollment":500},{"nctId":"NCT04742491","phase":"PHASE2, PHASE3","title":"Pre-Exposure Prophylaxis for Transgender Women in the US and South America","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2021-03-26","conditions":"HIV Prevention","enrollment":304},{"nctId":"NCT02591420","phase":"PHASE1","title":"Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT06766331","phase":"NA","title":"Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2028-04-03","conditions":"Opioid Use Disorder, HIV, Hepatitis C Virus","enrollment":60},{"nctId":"NCT07279129","phase":"PHASE1","title":"Decision Support Tool to Integrate PrEP Into Emergency Departments","status":"NOT_YET_RECRUITING","sponsor":"George Washington University","startDate":"2027-01-15","conditions":"HIV","enrollment":120},{"nctId":"NCT05979311","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-02-09","conditions":"HIV, HIV Infections","enrollment":473},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT05911360","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-01-31","conditions":"HIV, HIV Infections","enrollment":205},{"nctId":"NCT06613685","phase":"PHASE2, PHASE3","title":"Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-21","conditions":"HIV-1-infection","enrollment":675},{"nctId":"NCT05719441","phase":"PHASE2","title":"A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-08-19","conditions":"Acute HIV Infection","enrollment":48},{"nctId":"NCT05630755","phase":"PHASE3","title":"A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-17","conditions":"HIV-1 Infection","enrollment":514},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT02842086","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-09-02","conditions":"Pre-Exposure Prophylaxis of HIV-1 Infection","enrollment":5399},{"nctId":"NCT06630286","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-09","conditions":"HIV-1-infection","enrollment":609},{"nctId":"NCT06333808","phase":"PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-03-25","conditions":"HIV-1-infection","enrollment":577},{"nctId":"NCT05140954","phase":"PHASE2, PHASE3","title":"The Women TAF-FTC Benchmark Study","status":"COMPLETED","sponsor":"University of Washington","startDate":"2023-03-28","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT07115368","phase":"PHASE1","title":"Study of GS-1219 in Participants With HIV-1","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2025-08-11","conditions":"HIV-1-infection","enrollment":4},{"nctId":"NCT06891066","phase":"PHASE2","title":"A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-14","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":150},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT03164564","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-11-07","conditions":"HIV Infections","enrollment":3224},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT03360682","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2018-04-13","conditions":"HIV-1-infection, Solid Organ Transplant","enrollment":19},{"nctId":"NCT06101329","phase":"PHASE2","title":"Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-11-17","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":253},{"nctId":"NCT03512418","phase":"PHASE3","title":"Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-06-20","conditions":"HIV Infections, Substance Use Disorders","enrollment":30},{"nctId":"NCT06005610","phase":"PHASE2","title":"Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-04","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT04405271","phase":"PHASE3","title":"TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)","status":"TERMINATED","sponsor":"Hospital Italiano de Buenos Aires","startDate":"2020-07-31","conditions":"Healthcare Workers, COVID-19, SARS-CoV 2","enrollment":1378},{"nctId":"NCT06513312","phase":"PHASE2","title":"Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-07","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":268},{"nctId":"NCT02859558","phase":"PHASE2","title":"Early ART to Limit Infection and Establishment of Reservoir","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2017-01-24","conditions":"HIV-1 Infection","enrollment":195},{"nctId":"NCT01234116","phase":"PHASE4","title":"Post-Exposure Prophylaxis in Health Care Workers","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2011-02","conditions":"Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT03965923","phase":"PHASE3","title":"Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-01-09","conditions":"HIV Infections","enrollment":1104},{"nctId":"NCT04530630","phase":"PHASE4","title":"Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-11-09","conditions":"HIV Infections, Renal Transplant Rejection","enrollment":20},{"nctId":"NCT02470650","phase":"PHASE4","title":"Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive","status":"WITHDRAWN","sponsor":"Juan A. Arnaiz","startDate":"2015-06","conditions":"Patient Compliance, Antiretroviral Therapy Intolerance","enrollment":""},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT01778413","phase":"PHASE4","title":"Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine","status":"COMPLETED","sponsor":"Anna Cruceta","startDate":"2013-06-03","conditions":"HIV","enrollment":61},{"nctId":"NCT05549180","phase":"PHASE4","title":"Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2022-10-06","conditions":"HIV Infections","enrollment":84},{"nctId":"NCT05898841","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2023-05-26","conditions":"HIV Infections, Fatty Liver Disease","enrollment":63},{"nctId":"NCT04884139","phase":"PHASE4","title":"DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":554},{"nctId":"NCT04994509","phase":"PHASE3","title":"Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2021-08-30","conditions":"Pre-Exposure Prophylaxis of HIV Infection","enrollment":5368},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT01602822","phase":"PHASE4","title":"Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV","status":"TERMINATED","sponsor":"Kenneth H. Mayer, MD","startDate":"2012-02","conditions":"HIV","enrollment":11},{"nctId":"NCT04760691","phase":"PHASE1","title":"Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-03-01","conditions":"Hiv, Prophylaxis, Transgender","enrollment":13},{"nctId":"NCT04331704","phase":"PHASE4","title":"ANCHORS Alcohol & Sexual Health Study: UH3 Project","status":"RECRUITING","sponsor":"University of Florida","startDate":"2021-01-12","conditions":"Alcohol Use, Unspecified, Substance Use, Sex Behavior","enrollment":88},{"nctId":"NCT03771638","phase":"PHASE4","title":"DOT Diary Mobile App for Pre-Exposure Prophylaxis Adherence in Young Men","status":"COMPLETED","sponsor":"Public Health Foundation Enterprises, Inc.","startDate":"2019-02-01","conditions":"Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis","enrollment":100},{"nctId":"NCT04636437","phase":"PHASE4","title":"Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2021-07-27","conditions":"HIV Infections","enrollment":147},{"nctId":"NCT02652793","phase":"NA","title":"Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2015-11","conditions":"Human Immunodeficiency Virus","enrollment":31},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT05813964","phase":"PHASE3","title":"Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-06-05","conditions":"HIV/AIDS","enrollment":524},{"nctId":"NCT02656511","phase":"PHASE4","title":"Immediate Initiation of Antiretroviral Therapy During \"Hyperacute\" HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2015-12","conditions":"HIV","enrollment":74},{"nctId":"NCT02732730","phase":"PHASE4","title":"Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2016-10-12","conditions":"HIV","enrollment":451},{"nctId":"NCT07006246","phase":"PHASE4","title":"Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Professor Francois Venter","startDate":"2023-05-19","conditions":"HIV Infection","enrollment":1900},{"nctId":"NCT05072093","phase":"PHASE4","title":"Parrying the Pitfalls of PrEP: Project PEACH","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-11-20","conditions":"HIV, STI","enrollment":240},{"nctId":"NCT04692077","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-19","conditions":"HIV Infections","enrollment":9},{"nctId":"NCT05585307","phase":"PHASE1","title":"Study of Novel Antiretrovirals in Participants With HIV-1","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2022-10-26","conditions":"HIV-1-infection","enrollment":49},{"nctId":"NCT06374758","phase":"PHASE4","title":"Accelerated ART Initiation for PWHIV Who Are Out of Care","status":"RECRUITING","sponsor":"University of Missouri-Columbia","startDate":"2024-04-29","conditions":"HIV Infections, ART, Noncompliance, Patient","enrollment":120},{"nctId":"NCT05378399","phase":"PHASE3","title":"SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-12-20","conditions":"HIV Infections, Substance Use, Adherence, Medication","enrollment":40},{"nctId":"NCT05924438","phase":"PHASE3","title":"A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Professor Francois Venter","startDate":"2023-11-08","conditions":"HIV-1-infection","enrollment":600},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT01327651","phase":"PHASE2","title":"The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2011-08","conditions":"HIV Infections","enrollment":622},{"nctId":"NCT01276600","phase":"PHASE1","title":"Dose-Proportionality and Intra-Individual Variability of Intracellular TFV-DP and FTC-TP in Healthy Volunteers","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2011-01","conditions":"HIV","enrollment":32},{"nctId":"NCT03547908","phase":"PHASE3","title":"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-05-30","conditions":"HIV-1/HBV Co-Infection","enrollment":244},{"nctId":"NCT01140880","phase":"PHASE2","title":"Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2010-05","conditions":"HIV Seroconversion, Stimulant Abuse","enrollment":170},{"nctId":"NCT06158126","phase":"PHASE4","title":"UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-04-17","conditions":"Pre-exposure Prophylaxis, HIV Prevention, Pregnancy Related","enrollment":621},{"nctId":"NCT05602506","phase":"PHASE4","title":"Safety, Tolerability, and Efficacy of a Dose Reduction Strategy Based on Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-infected Adults","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-11-15","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT03386578","phase":"PHASE2","title":"Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-03","conditions":"HIV Infections","enrollment":780},{"nctId":"NCT06829082","phase":"","title":"Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia","status":"COMPLETED","sponsor":"Servicios de Salud IPS Suramericana S.A.S","startDate":"2024-11-15","conditions":"HIV Treatment","enrollment":161},{"nctId":"NCT05755204","phase":"","title":"A Pharmacist-run PrEP Program for Women","status":"TERMINATED","sponsor":"Orlando Immunology Center","startDate":"2023-06-21","conditions":"HIV Prevention","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["truvada"],"phase":"phase_3","status":"active","brandName":"daily TDF/FTC","genericName":"daily TDF/FTC","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TDF/FTC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase to prevent viral replication. Used for HIV-1 prevention (pre-exposure prophylaxis, PrEP), HIV-1 treatment as part of antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}